Streetbeat News

Price Targets

BNTX

Morgan Stanley analyst Matthew Korn has reiterated an Equal-Weight rating on BioNTech (NASDAQ:BNTX) and maintained a $124 price target.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 1:18 pm

ASND

Morgan Stanley analyst Vikram Purohit reiterated an Equal-Weight rating on Ascendis Pharma (NASDAQ:ASND) and maintained a $109 price target.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 1:17 pm

AMH

Morgan Stanley analyst Adam Kramer maintains an Equal-Weight rating on American Homes 4 Rent (NYSE:AMH) and raises the price target from $31.5 to $34.5.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 1:17 pm

SONN

EF Hutton analyst Michael King reiterates a Buy rating on Sonnet BioTherapeutics (NASDAQ:SONN) and maintains a $6.7 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 1:16 pm

PI

BWS Financial analyst Hamed Khorsand initiates coverage on Impinj (NASDAQ:PI) with a Sell rating and a price target of $45.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 1:10 pm

CNXC

Barrington Research analyst Vincent Colicchio has reiterated an Outperform rating on Concentrix (NASDAQ:CNXC) and maintained a $165 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 1:07 pm

RVPH

Over the past 3 months, 5 analysts have published their opinion on Reviva Pharmaceuticals (NASDAQ:RVPH) stock, with 4 bullish and 1 somewhat bullish ratings. The company has an average 12-month price target of $15.0, up 50% from the previous average of $10.0.

Portfolio Pulse from Benzinga Insights

June 26, 2023 | 1:01 pm

ALB

BURL

CAMP

GOOG

IONQ

MRCY

PLYA

RDNT

SHW

TSLA

UAL

Several analyst firms have updated their price targets and ratings for various US-listed companies, including RadNet, Albemarle, Tesla, CalAmp, Alphabet, Sherwin-Williams, IonQ, Mercury Systems, Playa Hotels & Resorts, United Airlines, and Burlington Stores.

Portfolio Pulse from Lisa Levin

June 26, 2023 | 1:00 pm

CDTX

HC Wainwright & Co. analyst Ed Arce reiterated a Buy rating on Cidara Therapeutics (NASDAQ:CDTX) and maintained a $6 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 12:55 pm